Patient-oriented biomedical investigation related to diagnosis, disease mechanisms, monitoring disease activity and new therapeutic approaches in rheumatic disease is the hallmark of the Johns Hopkins Division of Rheumatology. This research is structured around well-established disease-specific Centers of Excellence in scleroderma (Dr. Fred Wigley), lupus (Dr. Michelle Petri), arthritis (Dr. Joan Bathon), and vasculitis (Dr. John Stone). These clinical cohorts are coupled closely with a robust basic science program directed by Drs. Antony Rosen and Livia Casciola-Rosen. In recent years, this program has received outstanding institutional support, enabling significant growth, investment in shared equipment and infrastructure, and the initiation of multiple synergistic projects both within and outside the Division. Our Rheumatic Disease Research Core Center (RDRCC) proposal capitalizes upon the strong biomedical research base within the Division of Rheumatology, as well as additional outstanding talent from the broader scientific community at Johns Hopkins. The Hopkins RDRCC proposal comprises an Administrative Core (Core A) led by Drs. Antony Rosen and John Stone, and includes 2 Scientific Cores: 1) a Bioassay Core (Core B), led by Drs. James Mahoney, Mark Soloski, and Livia Casciola-Rosen;and 2) a Genotyping/Genomics Core (Core C), led by Dr. Kathleen Barnes, designed to foster new research within and beyond the Division's Disease Centers. Core A will promote interdisciplinary research through the cores, provide assistance with financial management, provide information technology solutions to maximize efficiency of translational research, and coordinate program enrichment activities. The Administrative core will also manage the Pilot and Feasibility program. Pilot studies chosen for the first year are tightly linked to the disease Centers and Cores. Pilot #1 will optimize assays to quantify clearance of apoptotic cells directly ex vivo in pediatric SLE patients. Pilot #2 will explore the association of genetic polymorphisms in granzyme B with specific phenotypes in scleroderma. Core B will provide assistance with patient sample acquisition, processing, storage, and distribution, as well as the provision of multiple immunological assays, including FACS, ELISA, immunohistology, and multiplex cytokine assays. Core C will perform, analyze, and interpret gene expression studies in a variety of human disease and control tissues and some mouse models. Core C will also oversee the design, performance and analysis of genetic association studies in well-defined human rheumatic phenotypes.

Public Health Relevance

This Rheumatic Disease Research Core Center provides systems and infrastructure to facilitate efficient research on humans with autoimmune rheumatic diseases. The synergies arising from coupling the diverse and well-resourced research base to the unusually rich collection of prospectively collected data from patients with rheumatic diseases through provision of central Cores provides unprecedented opportunities to enhance and accelerate discovery into the causes, mechanisms, diagnosis, therapy and prevention in these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053503-08
Application #
8535517
Study Section
Special Emphasis Panel (ZAR1-MLB (M1))
Program Officer
Mancini, Marie
Project Start
2006-03-01
Project End
2016-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
8
Fiscal Year
2013
Total Cost
$609,244
Indirect Cost
$239,058
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Singer, Benjamin D; Mock, Jason R; Aggarwal, Neil R et al. (2015) Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation. Am J Respir Cell Mol Biol 52:641-52
Langdon, Jacqueline M; Barkataki, Sangjucta; Berger, Alan E et al. (2015) RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice. Am J Hematol 90:14-Aug
Mock, J R; Garibaldi, B T; Aggarwal, N R et al. (2014) Foxp3+ regulatory T cells promote lung epithelial proliferation. Mucosal Immunol 7:1440-51
Liu, Qing-Rong; Rubio, Francisco J; Bossert, Jennifer M et al. (2014) Detection of molecular alterations in methamphetamine-activated Fos-expressing neurons from a single rat dorsal striatum using fluorescence-activated cell sorting (FACS). J Neurochem 128:173-85
Giles, Jon T; Darrah, Erika; Danoff, Sonye et al. (2014) Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One 9:e98794
Birnbaum, Julius; Duncan, Trisha; Owoyemi, Kristie et al. (2014) Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root Ganglia in Sjögren patients with neuropathic pain: case series of 10 patients and review of the literature. Medicine (Baltimore) 93:121-34
Aggarwal, Neil R; Tsushima, Kenji; Eto, Yoshiki et al. (2014) Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation. J Immunol 192:4453-64
Joseph, Christine G; Darrah, Erika; Shah, Ami A et al. (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 343:152-7
McCranor, Bryan J; Kim, Min Jung; Cruz, Nicole M et al. (2014) Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis 52:126-33
Geetha, D; Levine, S M; Manno, R L et al. (2014) BK virus replication in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Am J Nephrol 39:20-6

Showing the most recent 10 out of 37 publications